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Relationship between dialyzer reuse and anti-N-like antibodies
in chronic hemodialysis patients. One hundred eleven chronic
hemodialysis patients from five dialysis units were tested for the
presence of antibodies reactive with red blood cell N substance; 77
patients were available for follow-up study after 18 to 24 months.
Initially, 18 patients (16%) had serum anti-N-like antibodies. Thir-
teen of these patients were in a home dialysis program and were
reusing hollow fiber dialyzers. The other five had practiced hollow
fiber dialyzer reuse in the past. None of 37 patients using coil
dialyzers had anti-N-like antibody. On follow-up testing, anti-N-
like antibody persisted in all patients restudied except for one
who had a successful renal transplant. Anti-N-like antibodies de-
veloped in four additional patients: three were reusing hollow fiber
dialyzers at the time, but one had not reused dialyzers for 24
months. Statistical analyses indicated that dialyzer reuse, hollow
fiber dialyzers, and home dialysis were significantly related to the
presence of anti-N-like antibodies. We interpret the clinical and
statistical data to indicate that dialyzer reuse is the major clinical
factor in the development of anti-N-like antibody. The likely
mechanism involves the prolonged exposure of red cells trapped in
the dialyzer to formaldehyde used in preparing diaiyzers for reuse.
No adverse clinical effects of anti-N-like antibodies were evident in
our patients, but hemolysis and acute transplant failure have been
reported by others.
Relation entre le réemploi des dialyseurs et Ia presence d'anticorps
anti-N chez les malades en hémodialyse chronique. Cent onze mal-
ades soumis a l'hémodialyse chronique dans cinq unites de dialyse
ont etC Ctudiés pour déceler Ia presence d'anticorps rCagissant avec
Ia substance N des globules rouges; 77 malades ortt pu être suivis
ultérieurement pendant 18 a 24 mois. Au debut, 18 malades (16%)
avaient une substance sérique anti-N. Treize de ces malades étaient
en dialyse a domicile et rCutilisaient des dialyseurs fibres creuses.
Les cinq autres avaient rCemploye des dialyseurs fibres creuses
auparavant. Aucun des 37 malades qui utilisaient des dialyseurs a
bobine n'avaient d'anti-N. Au cours de Ia surveillance l'anti-N a
persistC chez tous les malades suivis sauf chez I'un d'eux qui a eu
une transplantation rCnale rCussie. L'anti-N est apparu chez quatre
autres malades. Trois de ceux-ci rCutilisaient des dialyseurs a fibres
creuses a ce moment là mais Ic quatriCme n'avait pas rCutilisC de
dialyseur depuis 24 mois. L'analyse statistique a montré que Ic
réemploi de dialyseurs, les dialyseurs a fibres creuses et
I'hémodialyse a domicile sont lies significativement a Ia presence de
l'anti-N. Le mécanisme vraisemblable implique 1'xposition pro-
longee des globules rouges sequestres dans Ic dialyseur a Ia formal-
dChyde utilisCe en vue de rCemploi. Aucun effet clinique de l'anti-N
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n'a Cté mis en evidence chez ces malades mais des hémodialyses et
des échecs immCdiats de transplantation ont été rapportés par
d'autres.
In the process of hemodialysis, a patient's blood is
removed from the usually friendly environment of the
vasculature and exposed to a variety of foreign sur-
faces and substances. In the ideal situation, the blood
should return to the patient with the plasma free from
added toxic material and with the cellular elements
unaltered. Unfortunately, the ideal has not been
achieved as evidenced by recent reports of systemic
and hematologic toxicity related to hemodialysis [1,
2].
This study was undertaken to explore another ap-
parently dialysis-related phenomenon, the presence
of antibodies to red blood cell N-antigen in chronic
hemodialysis patients. The reported increased fre-
quency of this generally rare antibody in dialysis
patients [3] prompted longitudinal investigation of
patients from five dialysis units in this community for
the presence of anti-N-like antibodies.
Methods
Patient population. One hundred and eleven
chronic hemodialysis patients from five dialysis units
were studied initially in the fall of 1974. Seventy-
seven of these patients were restudied 18 to 24
months after initial testing. Thirty-four patients had
moved to another geographical area or had expired
and, thus, were not available for retesting. The char-
acteristics of the dialysis units and patient popu-
lations are presented in Table 1. All patients were
dialyzed at least three times a week.
Dialysis units A and B used coil dialyzers (Travenol
Laboratories, Inc., Morton Grove, IL.) exclusively
with no dialyzer reuse. Dialysis unit C had used Kiil
dialyzers with reuse until 1970 to 1972 when there
was a gradual switch to hoiiow fiber artificial kidneys
(Cordis Dow, Cordis Corporation, Miami, FL). Hol-
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Table 1. Characteristics of the patient population at the time of initial study
Unit Program Dialyzer Reuse
No. of
patients
Average age
(range),yrs Sexa
Dialysis duration
(range),months
A Center Coil Never 28 50
(29to63)
16M, l2F 15
(13to66)
B Center Coil Never 9 50
(39to6l)
3M, 6F 28
(12to44)C Center HFAKb Previous 20 52
(25 to 65)
20M,0F 32
(3to87)D Center HFAK Previous 30 49
(22to76)
19M, I IF 16
(1to42)E Home HFAK Current 24 49
(25to60)
23M, IF 32
(7to71)
a M = male; F = female.b HFAK = hollow fiber artificial kidney.
low fiber kidneys were reused for all but a few pa-
tients until June, 1973, and again for a six-month
period ending five months prior to study. Unit D
used Cordis Dow hollow fiber kidneys and reused
dialyzers for a ten-month period ending 16 months
prior to study. All unit E patients were reusing hol-
low fiber kidneys at the time of initial study, but
stopped reuse 3 to 22 months prior to final study.
Hollow fiber artificial kidneys were delivered packed
with 2,5% formaldehyde for sterilization. Ku! dialy-
zers were routinely sterilized with 2% formaldehyde
prior to use, Coil dialyzers were sterilized with ethyl-
ene oxide and were not exposed to formaldehyde.
Dialysis units A and C used central delivery sys-
tems for dialysate which were sterilized one to three
times a week with a dilute formaldehyde solution.
Units D and E used individual delivery systems. These
systems were sterilized with dilute formaldehyde once
a week by home dialysis patients (unit E) and after
each dialysis in unit D. Unit B used no formaldehyde
in sterilizing its batch delivery systems. All units used
water purified by reverse osmosis,
Dialysis units C, D, and E followed the same pro-
tocol in preparing dialyzers for reuse. Following
dialysis, the blood compartment was flushed with 5 to
20 liters of tap water and then filled with 1.5% formal-
dehyde. The dialysate compartment was also filled
with formaldehyde. Prior to the next dialysis (about
40 hr later), the blood compartment was flushed with
900 ml of heparinized normal saline. The blood line
effluent was then tested for the presence of reducing
substances with Clinitest tablets (Ames Company,
Division Miles Laboratories, Inc., Elkhart, IN). The
dialyzer was used only if a negative Clinitest was
obtained. The dialysate compartment was flushed
with a minimum of 15 liters of sterile dialysate.
Laboratory methods. Venous blood was obtained
prior to dialysis, usually 42 hr after the completion of
the previous dialysis. Fresh serum was screened for
irregular blood group antibodies with commerically
available red cells possessing all common antigens
(Ortho Selectogen, Ortho Diagnostics, Raritan, NJ)
in saline at 4°, 20°, and 37°C. This was followed by
indirect Coombs testing with rabbit anti-human se-
rum (Ortho Diagnostics). Serum producing aggluti-
nation (0.08 ml) was then incubated with 0.04 ml of
red cells possessing specific common antigens (Ortho
Identogen) in saline for 30 mm at 4°, 20°, and 37°C.
Following centrifugation at 3400 rpm, the degree of
agglutination was graded from 0 to 4+ using macro-
scopic and microscopic reading if necessary. Serum
producing a pattern of agglutination consistent with
the presence of an anti-N antibody was titrated against
NN red cells at 20°C. The thermal range of activity of
the antibody was determined by incubating serum
with NN cells for 30 mm at 37°, 32°, 28°, 25°, 20°,
15°, and 4°C. Agglutination was then graded from 0
to 4+. Centrifugation was omitted from this pro-
cedure in order to avoid uncontrolled temperature
changes.
Direct antiglobulin testing (direct Coombs' test)
was performed at room temperature using rabbit
anti-human serum (Ortho Diagnostics). Three speci-
mens with positive direct Coombs' tests were tested
with specific rabbit anti-IgG and non-antigamma se-
rum (Ortho Diagnostics). An eluate was prepared
from one specimen by suspending washed red cells in
saline and incubating at 56°C for 10 mi NN red
cells were then incubated with the supernatant eluate
at 20° C, centrifuged, and examined for the presence
of agglutination. Red cell MN phenotypes were de-
termined for 18 patients whose serum contained an-
tibody consistent with anti-N.
In order to explore the immunglobulin nature of
the antibody, two sera were incubated with 0.1M 2-
mercaptoethan ol using Issitt's 1gM denaturation
technique [4]. Following this, the sera were incubated
with NN cells, and the degree of agglutination was
determined.
All estimates of agglutination were made by the
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Table 2. Occurrence of anti-N-like antibodies on initial study and after 18 to 24 months
Dialysis
unit
Initial study Follow-up study
No. of
patients
Patients with
anti-N-like
No. of
patients
Patients
initially with
anti-N-like
Patients with
anti-N-like on
follow-up testing
A
B
C
D
E
Total
28
9
20
30
24
111
0
0
2
3
13
18
15
6
17
20
19
77
0
0
1
3
10
14
0
0
2
3
13
18
same individual. The follow-up studies were per-
formed using the same antibody screening and
identification methods described above with incu-
bations performed at 20°C.
Howell and Perkins have indicated that the an-
tibody in question is directed against an antigen sim-
ilar but not identical to red cell N substance [3],
Therefore, in this paper, "anti-N-like" will refer to
the antibody found in hemodialysis patients and
"anti-N" to the non-dialysis-related antibody.
Clinical laboratory studies, including hematocrit,
hemoglobin, peripheral blood smears, and indirect
bilirubin, were routinely obtained at monthly inter-
vals from patients in units C and E (same dialysis
regimen). In addition, serum haptoglobin and lactic
dehydrogenase (LDH) concentrations and reti-
culocyte counts were obtained on at least three occa-
sions from all patients with anti-N-like antibodies.
Statistical Methods. Patients with anti-N-like anti-
bodies were compared to patients wit hout the an-
tibody with reference to the following clinical varia-
bles: dialyzer type, home or center dialysis, dialyzer
reuse, blood transfusions, hepatitis B antigenemia,
and antihypertensive and corticosteroid medications.
The comparisons were made by using a logit transfor-
mation of regression analysis for binomial variables,
with the dependent variable being the presence or
absence of antibodies [5], and by using Fisher's exact
method for the 2 X 2 table [61. Parametric data were
compared by Student's t test.
Results
Initial study. Eighteen of the Ill patients (16%) had
serum anti-N-like antibodies on initial testing (Table
2). Statistical analysis indicated that only hollow fi-
ber dialyzers, home dialysis, and dialyzer reuse were
significantly related to the presence ol anti-N-like.
Table 3 lists the patient distributions and the P value
(Fisher's exact method) for these significant varia-
bles. Dialyzer reuse significantly improved the fit of
the logit model when added to dialyzer type and
location of dialysis (P < 0.025).
Anti-N-like antibodies were found only in patients
using hollow fiber dialyzers (Table 4). All of these
patients had reused or were reusing dialyzers. Pa-
tients who were reusing dialyzers at the time of study
had a significantly greater frequency of anti-N-like
(13 of 24) than did patients who had stopped reuse
from 5 to 16 months previously (5 of 30; P <0.003).
The shortest duration of reuse in a patient with anti-
N-like antibody was five months.
Follow-up study. Seventy-seven of the original
group of 111 patients were able to be restudied (Ta-
bles 2 and 4). The 21 patients using coil dialyzers
from units A and B remained free of anti-N-like
antibodies. One of the 17 patients from unit C contin-
ued to have anti-N-like antibody, but another pa-
tient developed this antibody during the 21-month
interval between testing. This patient had reused hol-
low fiber dialyzers for a six-month period which
ended five months prior to the initial study. Three
patients from unit D retained serum anti-N-like anti-
bodies after 22 months; 17 patients remained free of
this antibody. Ten of 17 patients from unit E contin-
Table 3. Initial comparison of patients with and without
anti-N-like antibodies with reference to type of dialyzer,
center or home dialysis, and dialyzer reuse
Clinical variable
No. of
patients
Patients with
anti-N-like P valuea
Type of dialyzer:
HFAKb 74 18
<0.002
coil 37 0
Location
center 87 5
<0.0005
home 24 13
Reuse
none 57 0
<0.0005
any 54 18
P value as determined by Fisher's exact method.
b HFAK = hollow fiber artificial kidney.
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Table 4. Comparison of dialyzer reuse with presence of anti-N-like antibodies
Initial testing Follow-up testing
No. of Patients with No. of Patients with Total patients
Dialyzer Reuse patients anti-N-like patients anti-N-like with antiNlikea
Coil Never 37 0 21 0 0
HFAK Never 20 0 14 0 0
HFAK Previous 30 5 23 5 6
HFAK Current 24 13 19 13 16
Total Ill 18 77 IS 22
Includes those patients who were positive on initial testing but did not complete the study.
ued to have anti-N-like antibodies, and three addi-
tional patients developed antibodies during the inter-
val after initial testing but prior to discontinuation of
reuse. Thus, 18 of the 77 patients (23%) had serum
anti-N-like antibodies on completion of the study.
Thirteen of the 14 patients with serum anti-N-like
antibodies on initial testing continued to have anti-N-
like antibodies after 18 to 24 months. One patient
received a related donor kidney and attained good
renal function 11 months prior to repeat testing.
Anti-N-like antibodies were detectable at seven
months but not at 11 months. Six patients from unit
E continued to be free of anti-N-like antibodies; 13
patients, however, continued to have antibodies de-
spite discontinuing dialyzer reuse 7 to 19 months
prior to final testing.
Clinical and laboratory findings. None of the pa-
tients with serum anti-N-like antibodies had clinical
or laboratory evidence of hemolysis on initial or fol-
low-up study. The hematocrit values from patients
with and without antibodies from units C and E were
compared at initial and final study. On initial testing,
the average hematocrit values for patients with serum
anti-N-like antibodies was 29 + 9% (SD); for patients
without antibodies, it was 30 8%. After 18 to 24
months, the averages were 31 5% and 33 8%,
respectively. The averages were not statistically dif-
ferent on either occasion. Two patients with serum
anti-N-like antibodies required blood transfusions
during the study, both following major abdominal
surgery.
One patient with anti-N-like antibody received a
related donor kidney transplant without problems.
Another patient received two cadaver kidneys with
rejection occurring at seven days and five months.
Both kidneys were flushed with warm saline immedi-
ately prior to completion of the vascular anastamoses
and functioned well initially.
MN phenotypes were determined in 18 patients
with anti-N-like antibodies. Eleven were MN, six
were MM, and one was NN. Titers of anti-N-like
antibodies were determined for 13 sera and were gen-
erally very low: six were 1: 1, three 1:2, and one each
was 1:4, 1:8, 1:16, and 1:32.
The variation in thermal activity was great; how-
ever, all anti-N-like antibodies produced agglutina-
tion at 20°C. Three were active at 37°C, yet these
patients did not have signs of ongoing hemagglutina-
tion or hemolysis. Two of these patients possessed an
MM phenotype. The third patient was unique in that
his anti-N-like antibody was active at 37°C against
the NN cells used to identify the presence of the
antibody but not against his own NN cells at temper-
atures above 28°C.
Direct Coombs' tests were positive with 5 of the 15
samples tested. Specific anti-IgG serum testing was
positive with one and negative with two samples. The
latter two samples yielded positive tests with anti-
nongamma serum. Four of the patients with positive
direct Coombs' tests had MN red cell phenotypes;
one had type MM. The eluate obtained from the red
cells which had given a positive anti-IgG test did not
produce agglutination of NN cells. The sera from
three of the five patients with positive direct Coombs'
test also contained nonspecific cold agglutinins. Se-
rum incubated with 2-mercaptoethanol no longer
produced agglutination of NN red cells.
Discussion
Anti-N is an antibody directed against N antigen
of the red cell MN system. Removal of one N-acetyl-
neuraminic acid group (NANA) from MM antigen
produces NN antigenicity. Removal of another
NANA inactivates NN antigen. Thus, the MN sys-
tem appears to consist of a structural precursor (T
antigen), with one added NANA yielding NN an-
tigen and a second NANA producing MM antigen
[7]. Anti-N is a rarely found cold agglutinin, which
even more rarely causes hemolysis [8, 9].
This study confirms the increased frequency of
anti-N-like antibodies in patients on chronic hemo-
dialysis. Howell and Perkins initially described this
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phenomenon in 12 of 416 hemodialysis patients
screened for transplantation [3], and McLeish, Brath-
waite, and Peterson subsequently noted it in six of 40
patients [10]. Recently, Harrison et a! detected anti-
N-like antibodies in 15 of 33 home hemodialysis pa-
tients who were reusing dialyzers and in none of 28
center patients who had never reused dialyzers [11].
Twenty-two patients from an initial group of 111
(20%) were found to have anti-N-like antibodies dur-
ing this study. Analysis of the initial testing data
indicated that three clinical variables—home dialysis,
hollow fiber dialyzers, and dialyzer reuse--were signif-
icantly related to the presence of anti-N-like anti-
bodies. Home dialysis per se is unlikely to be biologi-
cally significant in the development of anti-N-like
antibodies since home patients are drawn from the
same population, use identical dialysis equipment
and water purification, follow the same treatment
schedule, and are trained in the same techniques as
used for center dialysis patients.
In this study, all patients with anti-N-like anti-
bodies used hollow fiber dialyzers; however, 9 of 12
patients in Howell and Perkins' series [3] and 2 of 15
in Harrison's study [11] used Kiil dialyzers. On initial
study, none of the 20 patients dialyzed with hollow
fiber kidneys without reuse had anti-N-like anti-
body, in contrast to 18 of 54 patients who reused
hollow fiber kidneys and had anti-N-lik antibodies
(P < 0.005). The patients who did not reuse dialyzers
had been on dialysis for an average duration of 24
months shorter than patients who reused dialyzers.
None of 14 patients who used hollow fiber dialyzers
without reuse, however, developed anti-N-like anti-
body during the subsequent 22 months. None of the
patients using coil dialyzers had anti-N-like anti-
body on initial or follow-up study (see Table 4).
While three patients from unit E developed anti-N-
like antibodies during the study when still reusing
dialyzers, an exception is the patient from unit C
who also developed anti-N-like antibody but had
stopped dialyzer reuse five months prior to initial
study and had not reused dialyzers during the 21
month study interval. He is the only patient in this
series definitely known to have developed anti-N-like
antibody at a time when dialyzers were not being
reused. Ongoing or previous dialyzer reuse signifi-
cantly improved the fit of the regression analysis
when added to the other two statistically significant
variables, location and dialyzer type. We conclude
that dialyzer reuse is the most significant clinical vari-
able related to the development of anti-N-like anti-
bodies in hemodialysis patients. The development of
anti-N-like antibody, however, in a patient who had
not reused dialyzers for 26 months suggests that
single use of formaldehyde-sterilized hollow fiber ar-
tificial kidneys may on occasion be sufficient to gener-
ate anti-N-like antibody.
The mechanism responsible for the development of
anti-N-like antibody appears to involve formal-
dehyde, as suggested by Howell and Perkins [3]. We
have recently demonstrated that MM red cells are
altered by exposure to dilute formaldehyde, such that
they agglutinate on incubation with anti-N-like anti-
body [12]. Formaldehyde is known to the capable of
altering protein structure [13] and presumably antig-
enicity. The mechanism by which formaldehyde al-
ters red cell MN antigenicity must account for the
development of anti-N-like antibodies in patients
with MM, MN, and NN phenotypes. No in vitro data
is available to detail this mechanism, but we feel that
a direct chemical reaction between formaldehyde and
a portion of the red cell MN structure is responsible
for the generation of a foreign antigen which stimu-
lates anti-N-like antibody formation. Formaldehyde
could form a methylene glycol ester [13] with the
NANA groups of M and N substance, thus masking
their presence, or its reducing action could indirectly
induce purely conformational changes. Formal-
dehyde exposure in patients on hemodialysis has been
recently reported to alter red cell metabolism by
NAD reduction, thus causing hemolytic anemia [14].
This mechanism seems unlikely in this setting.
We have observed agglutinated red bLood cells and
fragments adherent to the fibers of dialyzers prepared
as if for reuse, and others have found all cellular
elements on the membranes of dialyzers following a
single use [15, 16]. Thus, reuse sterilization provides
the opportunity for lengthy exposure of red cell antig-
enic surfaces to formaldehyde during the 40 hr of
sterilization prior to the next dialysis. Subsequent
hemodialysis may then wash some of the altered anti-
gens into the circulating blood for delivery into the
patient. If these substances are sufficiently antigenic
and the patient's immune system competent, anti-N-
like antibody will be formed.
Anti-N-like antibody has been reported to dis-
appear within 7 to 11 months following successful
renal transplantation [3]. In the one successfully
transplanted patient in our series, anti-N-like anti-
body was still detectable after seven months, but
had disappeared at 11 months. The anti-N-like anti-
bodies have not disappeared in any ol the patients
remaining on dialysis, despite the discontinuation of
dialyzer reuse 9 to 38 months prior to the end of the
study (average, 18 11 months). The persistence of
anti-N-like antibodies could be related to continued
generation of a very small amount of altered N an-
tigen due to the residual formaldehyde present after
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even the most vigorous dialyzer preparation. The
Clinitest method for detecting residual formaldehyde
is relatively crude and will only detect concentrations
above 15 iig/ml. The method used to prepare new
hollow fiber dialyzers for use in units C, D, and E
could leave a residual formaldehyde concentration
approaching that limit [17]. This residual formal-
dehyde effect on red cells does not seem sufficient to
generate the development of detectable anti-N-like
antibody in most individuals, but it may well be able
to generate enough antigen to continuously stimulate
previously sensitized anti-N-like-producing cells. On
occasion, this residual formaldehyde may produce a
quantity of altered N-antigen sufficient to generate
anti-N-like antibody in a patient who has never
reused dialyzers or who has discontinued dialyzer
reuse, as in the patient from unit C described pre-
viously.
The presence of anti-N-like in dialysis patients is
usually not manifested clinically. A patient reported
by Harrison et al had increased transfusion needs
until dialyzer blood lines were insulated and the
dialysate temperature raised to 38°C [II]. In our
series, there was no evidence of hemolysis, increased
transfusion needs, or anemia disproportionate to that
seen in patients without anti-N-like antibodies. The
direct Coombs' test was positive in 5 of 15 patients
with anti-N-like antibodies, in contrast to its presence
in all of the patients reported by McLeish et al [10].
None of the 12 patients reported by Howell and
Perkins had a positive Coombs' test [3]. The in-
activation of the anti-N-like antibody on incubation
in 2-mercaptoethanol suggests that it is of the 1gM
class [4].
Since anti-N-like antibodies are reactive at cold
temperatures, any MN or NN phenotype patient pos-
sessing anti-N-like antibody who receives a chilled
organ in transplant has the potential for autoaggluti-
nation of red cells in the cold graft organ. Two in-
stances of acute graft failure due to this phenomenon
have been reported [3, 18]. Since MN group antigens
are found in mammary glands, salivary glands, kid-
ney, and liver [19], antibodies to these tissues may
produce deleterious effects not apparent at this time.
The practice of reusing dialyzers has important
economic considerations. Problems with altered
membrane characteristics and pyrogen reactions do
occur, but have not been major in our experience.
Anti-N-like antibodies have not caused apparent clin-
ical problems in our patients. The generation of an
antibody directed against a substance present in
many tissues, however, is significant enough in itself
to warrant consideration of discontinuance of dialy-
zer reuse or the adoption of a non-formaldehyde
process for resterilizing dialyzers and perhaps even
for initial dialyzer sterilization.
Achnowledgments
This work was presented in part at the Eighth
Annual Meeting of the American Society of Neph-
rology, Washington, D. C., November 25—26, 1975.
We acknowledge the technical assistance of Vivian
Mega, M. T. (ASCP) BB; the cooperation of Drs.
Richard Holman, Wagner Schorr, Michael Persoff,
Jeffrey Jennings, S. Robert Contiguglia, Melvyn
Klein, and Jeffrey Mishell in providing access to their
patients; the assistance of Drs. Philip Archer and
Richard Jones in the statistical analyses; and the as-
sistance of Daisy Rodarte in preparing the manu-
script.
Reprint requests to Dr. W. D. Kaehny, Renal Section III C.
Veterans Administration Hospital, Denver, Colorado 80220, U.S.A.
References
I. K.JFLLSTRAND CM, EATON JW, YAWATA Y, SWOFFORD H,
KOLPIN CF, BUSELMEIR TJ, VONHARTITZSCI-I B, JACOB HS:
Hemolysis in dialyzed patients caused by chloramines. Neph-
ron 13:427—433, 1974
2. MANZLER AD, SCHREINER AW: Copper induced acute he-
molytic anemia: A new complication of hemodialysis. Ann
Intern Med 73:409—4 12, 1970
3. HOWELL ED, PERKINS HA: Anti-N-like antibodies in the sera
of patients undergoing chronic hemodialysis. Vox Sang
23:291—299, 1972
4. ISSITT PD: Applied Blood Group Serology. Oxnard, CA, Bec-
ton, Dickinson, and Company, 1970, p. 2!
5. ARMITAGE P: Statistical Merhods in Medical Research. Oxford,
Blackwell Scientific Publications, 1971, p. 375
6. DixoN WJ: Introduction to Statistical Analysis (3rd ed). New
York, McGraw-Hill, 1969, p. 242
7. SPRINGER GF, DESAI PR: Common precursors of human
blood group MN specificities. Biochem Biophys Res Commun
61:470—475, 1974
8. BOWMAN HS, MARSH WL, SCHUMACHER HR, OVEN R, RE!-
HART J: Auto anti-N-immunohemolytic anemia in infectious
mononucleosis. Am J Cliii Pathol 61:465—472, 1974
9, HINZ CF, BOYER JT: Dysgammaglobulinemia in the adult
manifested as autoimmune hemolytic anemia: Serologic and
immunochemical characterization of an antobody of unusual
specificity. N Engl I Med 269:1329—1335, 1963
10. MCLEISH WA, BRATH WAITE AF, PETERSON PM: Anti-N anti-
bodies in hemodialysis patients. Transfusion 15:43—45, 1975.
11. HARRISON PB, JANSSON K, KRONENBERG H, MAHONY JF,
TILLER D: Cold agglutinin formation in patients undergoing
haemodialysis: A possible relationship to dialyzer re-use. AustNZJ Med 5:195—197, 1975
12. WHITE WL, MILLER GE, KAEHNY WD: Formaldehyde in the
pathogenesis of hemodialysis-related anti-N antibodies.
Transfusion, in press
13. FRENCH D, EDSALL JT: The reactions of formaldehyde with
amino acids and proteins. Adv Protein Chem 2:277—335, 1945
Dudyzer reuse and anti-N-like antibodies 65
14, ORRINGER EP, MATTERN WD: Formaldeh)de-induced he-
molysis during chronic hemodialysis. NEngli Med 294:1416—
1420, 1976
15. MARSHALL JW, AHEARN DJ, NOTHUM RJ, ESTERLY J, NOLPH
KD, MAHER JF: Adherence of blood components to dialyzer
membranes: Morphological studies. Nephr9n 12:157—170,
1974
16. ZUCKER WH, SHINODA BA, MASON RG: Experimental inter-
actions of components of hemodialysis units with human
blood. Am J Pathol 75:139—160, 1974
17. OGDEN DA, MYERS LE, ESKELSON CD, ZIEGLER EJ: latro-
genie administration of formaldehyde to hemodialysis pa-
tients. Proc Clin Dial Transpi Forum 3:141—145, 1973
18. BELZER FO, KouNTz SL, PERKINS HA: Red cell cold autoagg-
lutinins as a cause of failure of renal alltotransplantation.
Transplantation 11:422—424, 1971
19. SPRINGER GF, DESAI PR, SCANLON EF: Blood group MN
precursors as human breast carcinoma-associated antigens
and "naturally" occurring human cytotoxins against them.
Cancer 37:169—176, 1976
